COLLABORATION

Moderna to Acquire Oriciro Genomics for US $ 85 million

Moderna has announced it will acquire Japanbased DNA supplier OriCiro Genomics K.K (OriCiro) for $85m, marking the US Company’s first acquisition since its 2010 launch.

Through the acquisition, Moderna will get access to OriCiro's equipment for cell-free plasmid DNA synthesis and amplification, a form of DNA molecule used in the production of mRNA.

Fda Approval

According to the firm, the medicines and vaccines in Moderna's portfolio will be supported by OriCiro's synthetic biology and enzyme technology.

The development of therapeutics and vaccines for infectious diseases, immunooncology, rare diseases, cardiovascular diseases, and autoimmune diseases has been made possible by Moderna's mRNA platform, which is built on ongoing advances in basic and applied mRNA science, delivery technology, and manufacturing. For the previous eight years, Moderna has been recognised by Science as a top biopharmaceutical employer.

The mission of OriCiro Genomics, established in December 2018, is to develop and commercialise cell-free plasmid DNA synthesis and amplification methods for use in gene/cell-based therapeutics and synthetic biology.

Read the complete post

TScan Therapeutics Announces FDA Approvals for Solid Tumor Treatment in the United States

The U.S. Food and Drug Administration (FDA) has approved TScan Therapeutics' investigational new drug (IND) applications for T-Plex, TSC204-A0201, and TSC-204-C0702.

T-Plex will allow patients to get individualized combinations of T cell receptor (TCR)-engineered T cell therapies (TCR-T) based on the HLAs and targets expressed in their tumours. It will serve as the principal IND for TScan's solid tumour programme.

Each patient's individual TCRs will be chosen from the ImmunoBank of TScan. Each distinct TCR-T will be submitted as a secondary IND with a reference to the T-Plex primary IND.

In addition to the T-Plex IND, TScan also submitted secondary INDs for the original TCR-T products, TSC-204-A0201 and TSC-204-C0702.

With the approval of these INDs, TScan is now working to begin a multicenter Phase I clinical trial in order to determine the preliminary efficacy, safety, and viability of repeating multiplexed TCR-T doses.

Patients with melanoma, non-small cell lung cancer, head and neck cancer, ovarian cancer, and cervical cancer will participate in this experiment.

Read the complete post